Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rocky Mountain Spotted Fever01:26

Rocky Mountain Spotted Fever

Rocky Mountain Spotted Fever (RMSF) is a severe tick-borne illness caused by Rickettsia rickettsii, a Gram-negative, coccobacillary bacterium. This pathogen is an obligate intracellular parasite, requiring a host cell for replication. Transmission occurs through the bite of an infected tick. In the United States, the most important vectors are Dermacentor variabilis (American dog tick) and Dermacentor andersoni (Rocky Mountain wood tick), though other tick species may also serve as vectors.
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma CXCL13 and fibrosis biomarkers in COVID-19 compared with idiopathic pulmonary fibrosis.

Scientific reports·2026
Same author

Occupational category, job type, and sarcoidosis: Findings from a French multicenter study.

Pulmonology·2026
Same author

Immunological efficacy and safety of influenza vaccination in adults with sarcoidosis: the SARCOVAC study.

Vaccine·2026
Same author

Aspergillosis complicating idiopathic lung fibrosis: a multicentric series.

Respiratory medicine·2026
Same author

Design of PROGRESSION-IPF: A pragmatic, open-label, randomized trial of patients with progressive disease in idiopathic pulmonary fibrosis.

Respiratory medicine and research·2026
Same author

Efficacy and safety of danazol for pulmonary fibrosis or bone-marrow failure associated with telomere-related gene mutation.

ERJ open research·2026

Related Experiment Videos

[Sarcoidosis treatment].

Hilario Nunes1, Yurdagul Uzunhan, Daniel Bonnet

  • 1Service de pneumologie, hôpital Avicenne AP-HP, université Paris-Nord 13, 93009 Bobigny cedex, France. hilario.nunes@avc.aphp.fr

La Revue Du Praticien
|July 26, 2008
PubMed
Summary
This summary is machine-generated.

Sarcoidosis treatment focuses on managing symptoms and complications, not the cause. Systemic therapy is reserved for severe or progressive cases, with corticosteroids as the primary approach.

Related Experiment Videos

Area of Science:

  • Pulmonology
  • Immunology
  • Rheumatology

Context:

  • Sarcoidosis is a multisystem inflammatory disease characterized by non-caseating granulomas.
  • While often self-limiting, some patients develop chronic or severe manifestations requiring intervention.

Purpose:

  • To outline current therapeutic strategies for sarcoidosis.
  • To define indications for systemic therapy and preferred treatment regimens.

Summary:

  • Systemic corticosteroids are the first-line treatment for sarcoidosis, typically for at least 12 months.
  • Steroid-sparing agents like hydroxychloroquine, methotrexate, or azathioprine are used for high-threshold disease.
  • Methotrexate is a preferred alternative for corticosteroid-contraindicated or resistant cases, with a broad range of other agents available for refractory disease.

Impact:

  • Provides a framework for managing sarcoidosis, optimizing patient outcomes.
  • Highlights the importance of individualized treatment based on disease severity and organ involvement.
  • Informs clinical decision-making for healthcare providers treating sarcoidosis patients.